745 related articles for article (PubMed ID: 25750269)
21. Recent advances in therapy for glioblastoma.
Clarke J; Butowski N; Chang S
Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224
[TBL] [Abstract][Full Text] [Related]
22. Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.
von Neubeck C; Seidlitz A; Kitzler HH; Beuthien-Baumann B; Krause M
Br J Radiol; 2015 Sep; 88(1053):20150354. PubMed ID: 26159214
[TBL] [Abstract][Full Text] [Related]
23. Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme.
Zincircioglu SB; Kaplan MA; Isikdogan A; Cil T; Karadayi B; Dirier A; Kucukoner M; Inal A; Yildiz I; Aggil F; Donmez O; Urakci Z; Pekkolay Z; Firat U
J BUON; 2012; 17(1):124-7. PubMed ID: 22517705
[TBL] [Abstract][Full Text] [Related]
24. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
25. Towards tailored therapy of glioblastoma multiforme.
Rekers NH; Sminia P; Peters GJ
J Chemother; 2011 Aug; 23(4):187-99. PubMed ID: 21803695
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
[TBL] [Abstract][Full Text] [Related]
27. Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients.
Lee IY; Hanft S; Schulder M; Judy KD; Wong ET; Elder JB; Evans LT; Zuccarello M; Wu J; Aulakh S; Agarwal V; Ramakrishna R; Gill BJ; Quiñones-Hinojosa A; Brennan C; Zacharia BE; Silva Correia CE; Diwanji M; Pennock GK; Scott C; Perez-Olle R; Andrews DW; Boockvar JA
Future Oncol; 2024 Mar; 20(10):579-591. PubMed ID: 38060340
[TBL] [Abstract][Full Text] [Related]
28. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Neagu MR; Reardon DA
Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
[TBL] [Abstract][Full Text] [Related]
29. Glioblastoma multiforme: evidence-based approach to therapy.
Nicholas MK
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S23-7. PubMed ID: 18076314
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cell immunotherapy for glioblastoma.
Polyzoidis S; Ashkan K
Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
[TBL] [Abstract][Full Text] [Related]
31. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
[TBL] [Abstract][Full Text] [Related]
32. [New therapeutic options in therapy of glioblastoma multiforme].
Lakomý R; Burkon P; Burkonová D; Jancálek R
Klin Onkol; 2010; 23(6):381-7. PubMed ID: 21351415
[TBL] [Abstract][Full Text] [Related]
33. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
34. Treatment options for glioblastoma.
Chamberlain MC
Neurosurg Focus; 2006 Apr; 20(4):E19. PubMed ID: 16709025
[TBL] [Abstract][Full Text] [Related]
35. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
36. Agenus cancer vaccine extends survival of GBM patients.
Riedmann EM
Hum Vaccin Immunother; 2014; 10(2):252-3. PubMed ID: 24963517
[No Abstract] [Full Text] [Related]
37. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
Shibui S; Narita Y; Mizusawa J; Beppu T; Ogasawara K; Sawamura Y; Kobayashi H; Nishikawa R; Mishima K; Muragaki Y; Maruyama T; Kuratsu J; Nakamura H; Kochi M; Minamida Y; Yamaki T; Kumabe T; Tominaga T; Kayama T; Sakurada K; Nagane M; Kobayashi K; Nakamura H; Ito T; Yazaki T; Sasaki H; Tanaka K; Takahashi H; Asai A; Todo T; Wakabayashi T; Takahashi J; Takano S; Fujimaki T; Sumi M; Miyakita Y; Nakazato Y; Sato A; Fukuda H; Nomura K
Cancer Chemother Pharmacol; 2013 Feb; 71(2):511-21. PubMed ID: 23228988
[TBL] [Abstract][Full Text] [Related]
38. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
Ung N; Yang I
J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
[TBL] [Abstract][Full Text] [Related]
39. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
Londhe VY; Date V
Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
[TBL] [Abstract][Full Text] [Related]
40. Designer therapies for glioblastoma multiforme.
Sathornsumetee S; Rich JN
Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
